ArticleActa parasitologica2026
Antiprotozoal Activity of Artemisia vulgaris and Berberis vulgaris Against Leishmania major and Trichomonas vaginalis.
Article in Acta parasitologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLeishmania major and Trichomonas vaginalis infections pose a significant global health burden, while current treatments are limited by toxicity, resistance, and restricted accessibility. This study aimed to evaluate the in vitro and ex vivo antileishmanial effects of Artemisia vulgaris and Berberis vulgaris extracts against L. major, as well as their in vitro antitrichomonal activity against T. vaginalis trophozoites.
methodsEthanolic extracts of A. vulgaris and B. vulgaris were tested against L. major promastigotes, intracellular amastigotes, and T. vaginalis trophozoites. Parasite viability was determined by CellTiter-Glo®, microscopy, and rescue–transformation assays, and selectivity indices (SI) were calculated. Amphotericin B and metronidazole served as reference drugs.
resultsBoth extracts exhibited low cytotoxicity in THP-1 macrophages (A. vulgaris CC₅₀ = 465.2 µg/mL; B. vulgaris = 357.7 µg/mL). Against L. major, B. vulgaris showed greater potency (IC₅₀ = 76.8 µg/mL; SI = 4.7 for amastigotes) than A. vulgaris (IC₅₀ = 179.7 µg/mL; SI = 2.6). Both extracts reduced intracellular parasite burden in a dose-dependent manner, achieving complete clearance at non-cytotoxic concentrations (≥ 300 µg/mL). In T. vaginalis, the extracts induced concentration-dependent inhibition, with IC₅₀ values of 68.9 µg/mL (B. vulgaris, SI = 5.2) and 104.4 µg/mL (A. vulgaris, SI = 4.5).
conclusionBoth extracts exhibited selective, dose-dependent antiprotozoal activity, with B. vulgaris showing superior efficacy, particularly against intracellular L. major and T. vaginalis. These results highlight their potential as natural antiprotozoal sources, warranting further studies on active constituents, mechanisms, and in vivo efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.